Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | RET mutant |
| Therapy | Zeteletinib |
| Indication/Tumor Type | medullary thyroid carcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RET mutant | medullary thyroid carcinoma | sensitive | Zeteletinib | Phase I | Actionable | In a Phase I trial, Zeteletinib (DS-5010) treatment led to an objective response rate (ORR) of 28% (28/101), disease control rate (DCR) of 58% (59/101), median progression-free survival (mPFS) of 7.16 mo, and median duration of response (mDOR) of 11.10 mo in patients with RET-altered advanced solid tumors, with an ORR of 30% (8/27, all PR), DCR of 74% (20/27), mPFS of 12.75 mo, and mDOR of 19.15 mo in medullary thyroid cancer patients harboring a RET mutation including M918T (PMID: 40992271; NCT03780517). | 40992271 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (40992271) | BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter study. | Full reference... |